Fidelity International’s BridgeBio Pharma BBIO Stock Holding History

Fidelity International’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.6M	Buy	1,002,260 +1,002,172	+1,138,832%	+$70.2M	0.05%	288
2026 Q1	$6.54K	Buy	+88	New	+$6.38K	﹤0.01%	1095
2019 Q3	–	Sell	-289,448	Closed	-$7.81M	–	894
2019 Q2	$7.81M	Buy	+289,448	New	+$7.89M	0.01%	495

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fidelity International's BBIO Position: Q2 2026 in Review

Fidelity International increased its BridgeBio Pharma (BBIO) stake by 1,138,832% in Q2 2026, buying an estimated $70.2M and bringing the position to 1,002,260 shares worth $74.6M. The position accounts for 0.05% of the portfolio, ranked #288.

Fidelity International first reported a position in BBIO in Q2 2019 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Fidelity International held 1,002,260 shares of BridgeBio Pharma worth $74.6M as of Q2 2026.
Fidelity International bought 1,002,172 BridgeBio Pharma shares in Q2 2026, an estimated $70.2M.
BridgeBio Pharma made up 0.05% of Fidelity International's portfolio in Q2 2026, its #288 holding.
Fidelity International first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 3 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.